Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer

Pancreatic cancer is a devastating disease with a poor prognosis. Novel chemotherapeutics in pancreatic cancer have shown limited success, illustrating the urgent need for new treatments. Lurbinectedin (PM01183; LY-01017) received FDA approval in 2020 for metastatic small cell lung cancer on or afte...

Full description

Bibliographic Details
Main Authors: Tej Tummala, Ashley Sanchez Sevilla Uruchurtu, Arielle De La Cruz, Kelsey E. Huntington, Andrew George, Nicholas R. Liguori, Leiqing Zhang, Lanlan Zhou, Abbas E. Abbas, Christopher G. Azzoli, Wafik S. El-Deiry
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Current Oncology
Subjects:
lurbinectedin (ZEPZELCA™)
irinotecan
5-fluorouracil (5-FU)
pancreatic cancer
combination therapy
γH2AX
Online Access:https://www.mdpi.com/1718-7729/30/11/696

Internet

https://www.mdpi.com/1718-7729/30/11/696

Similar Items